文献速递神经免疫

晚发型复发缓解型多发性硬化疾病修正治疗的有效性

Effectiveness of Disease-Modifying Therapies in Patients With Late-Onset Relapsing-Remitting Multiple Sclerosis.
PubMed 文献 · Neurology · 2025-08-07

该单中心前瞻性纵向分析比较了晚发型与成人型复发缓解型多发性硬化患者启动疾病修正治疗后的2年结局。调整基线变量后,两组在复发、残疾进展、MRI活动及NEDA丧失方面均无显著差异,提示不应因发病年龄较大而影响治疗决策。

要点

  • 晚发型与成人型RRMS患者启动DMT后2年复发风险无显著差异。
  • 两组残疾进展、MRI活动及NEDA丧失风险在调整后均相似。
  • 因副作用停药比例在两组间相似,不应因年龄偏大而 bias 治疗决策。

核心结论

  • 晚发型与成人型RRMS患者启动DMT后2年治疗结局相似。
  • 当患者存在炎症活动证据时,不应因发病年龄较大而影响治疗决策。

研究设计与样本

  • 单中心、纵向、前瞻性分析,纳入1,494例成人型RRMS和150例晚发型RRMS患者。
  • 晚发型RRMS定义为首次症状发病年龄>45岁,成人型为18至45岁。
  • 患者启动二甲富马酸、芬戈莫德、醋酸格拉替雷、那他珠单抗或奥瑞珠单抗治疗,随访至第1年和第2年。

主要发现

  • 第1年调整后,复发概率(Coeff=-0.07;95%CI -0.19至0.04,p=0.24)、EDSS进展(OR 1.43,95%CI 0.69-2.93,p=0.33)、MRI活动(OR 0.77;95%CI 0.21-2.83,p=0.70)及NEDA丧失(HR 0.93;95%CI 0.73-1.18,p=0.58)均无差异。
  • 第2年调整后,复发(Coeff=-0.04;95%CI -0.19至0.11,p=0.60)、EDSS进展(OR 1.33;95%CI 0.69-2.93,p=0.33)、MRI活动(OR 1.30;95%CI 0.38-4.38,p=0.67)及NEDA丧失(HR 0.99;95%CI 0.77-1.26,p=0.96)均无差异。
  • 以50岁为年龄切点重复分析,结果相似。
  • 因副作用停用DMT的患者比例在两组间相似。

关键数值与推荐

  • 晚发型RRMS定义为首次症状发病年龄>45岁,成人型为≥18岁且≤45岁。
  • 研究提供III级证据:晚发型RRMS患者接受DMT的2年结局与成人型RRMS相当。

临床怎么用

  • 对于存在炎症活动证据的晚发型RRMS患者,不应仅因年龄较大而延迟或限制DMT的使用。
  • 治疗决策应基于疾病活动性而非发病年龄。

局限性

  • 观察性设计。
  • 单中心研究。
  • 晚发型RRMS组样本量相对较小。
  • 治疗组间基线不平衡且结局评估未设盲。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The benefit of disease-modifying therapies (DMTs) in relapsing-remitting multiple sclerosis (RRMS) is believed to decrease with age. We aimed to compare disease outcomes with DMTs between patients with late-onset RRMS (LO-RRMS) and adult-onset RRMS (AO-RRMS). METHODS: This was a single-center, longitudinal, prospective analysis of patients who fulfilled the following criteria: (1) a diagnosis of RRMS and (2) initiation of a new DMT (dimethyl fumarate, fingolimod, glatiramer acetate, natalizumab, and ocrelizumab) within 3 months. Patients were followed up at years 1 and 2. We compared treatment outcomes (relapses, radiologic activity, disability progression, and no evidence of disease activity [NEDA]) between LO-RRMS (defined as age at onset of first symptom >45 years) and AO-RRMS (≥18 years and 45 years) using Poisson, logistic, and Cox regression models while adjusting for baseline variables. The analyses were repeated with an age cutoff of 50 years. RESULTS: We studied 1,494 patients with AO-RRMS (mean age at onset: 29.6 years, 71% female) and 150 patients with LO-RRMS (50.2 years, 73% female) at treatment initiation. At DMT commencement, patients with LO-RRMS had shorter disease duration, higher Expanded Disability Status Scale (EDSS), more comorbidities, and were more likely to be treatment naive than patients with AO-RRMS. However, when adjusted, there were no differences in the probability of relapses (Coeff = -0.07; 95% CI -0.19 to 0.04, p = 0.24), EDSS progression (odds ratio [OR] 1.43, 95% CI 0.69-2.93, p = 0.33), MRI activity (OR 0.77; 95% CI 0.21-2.83, p = 0.70), and losing NEDA status (hazard ratio [HR] 0.93; 95% CI 0.73-1.18, p = 0.58) at year 1. Similar results were observed at year 2 in relapses (Coeff = -0.04; 95% CI -0.19 to 0.11, p = 0.60), EDSS progression (OR 1.33; 95% CI 0.69-2.93, p = 0.33), MRI activity (OR 1.30; 95% CI 0.38-4.38, p = 0.67), and loss of NEDA status (HR 0.99; 95% CI 0.77-1.26, p = 0.96). Similar results were observed using an age cutoff of 50 years. The percentages of patients who stopped DMTs because of side effects were similar between AO-RRMS and LO-RRMS. DISCUSSION: Treatment outcomes over 2 years were similar between LO-RRMS and AO-RRMS. This indicates that care should be taken not to bias treatment decisions due to older age at onset of MS when patients demonstrate evidence of inflammatory activity. Limitations are the observational design, the single-center setting, and a relatively small LO-RRMS group. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that patients with LO-RRMS have comparable outcomes with DMTs as patients with AO-RRMS over a 2-year period; this rating is because of baseline imbalances between treatment groups and a nonmasked outcome assessment.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Al-Araji S, Moccia M, Jha A, et al. Effectiveness of Disease-Modifying Therapies in Patients With Late-Onset Relapsing-Remitting Multiple Sclerosis. Neurology. 2025. PMID: 40773722. doi:10.1212/WNL.0000000000213967

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。